Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Page 20
GLP-1 and Amylin Feeding Study in Rats
A rat study found stronger feeding suppression when GLP-1 and amylin receptor pathways were activated together in one brain region.
Iran's GLP-1 Cost-Effectiveness Model
An Iranian 68-week model found semaglutide cost-effective at its threshold, while tirzepatide offered more benefit at a higher estimated cost.
Semaglutide, Depression and HIV
Depressive-symptom scores were stable overall after semaglutide began in 354 people with HIV, but the uncontrolled study cannot prove psychiatric safety.
Semaglutide and Handgrip Strength
A new systematic review found very low-certainty evidence on handgrip strength after semaglutide, not proof of strength preservation or loss.
How Oral Semaglutide Enhancers Differ
A preclinical comparison of SNAC, DDM and LLC found distinct intestinal transport and barrier-response patterns for semaglutide.
Semaglutide vs Revisional Surgery
A retrospective cohort compared semaglutide with revisional bariatric surgery after recurrent weight gain following a primary operation.
TAB trial: tirzepatide plus buprenorphine
The recruiting TAB trial will test tirzepatide added to buprenorphine for opioid use disorder, but its design paper reports no outcomes.
Tirzepatide and Lithium: A New Case Report
A newly indexed case report links tirzepatide and lithium toxicity, but its accessible record contains no clinical details or evidence of causation.
Tirzepatide in a UK digital cohort
A 630,545-person UK tirzepatide cohort reported substantial weight loss, but missing weights and self-pay selection limit interpretation.
ADCY4 Atherosclerosis Mouse Study
A laboratory study links endothelial ADCY4 to vascular inflammation and semaglutide effects in cells and mice, not to a new human treatment result.
GLP-1 Drugs and AF in Obesity With CKD
A matched cohort linked GLP-1 receptor agonist use with less one-year atrial fibrillation in non-diabetic adults with obesity and CKD.
GLP-1 Therapies in ESRD: 2026 Meta-Analysis
A 2026 meta-analysis pooled 19 studies and 388 patients with end-stage renal disease, but most treatment-specific estimates concerned semaglutide.